136 related articles for article (PubMed ID: 38853537)
21. A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor.
Jeong SH; Vorachitti M; Fuentes F
Cureus; 2023 May; 15(5):e39012. PubMed ID: 37378199
[TBL] [Abstract][Full Text] [Related]
22. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
[TBL] [Abstract][Full Text] [Related]
23. A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery.
Osafehinti DA; Okoli OJ; Karam JG
AACE Clin Case Rep; 2021; 7(1):20-22. PubMed ID: 33851014
[TBL] [Abstract][Full Text] [Related]
24. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review.
Morace C; Lorello G; Bellone F; Quartarone C; Ruggeri D; Giandalia A; Mandraffino G; Minutoli L; Squadrito G; Russo GT; Marini HR
Metabolites; 2024 May; 14(5):. PubMed ID: 38786741
[TBL] [Abstract][Full Text] [Related]
25. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
[TBL] [Abstract][Full Text] [Related]
26. Sodium-Glucose Cotransporter-2 Inhibitor-associated Euglycemic Diabetic Ketoacidosis: Lessons From a Case Series of 4 Patients Undergoing Coronary Artery Bypass Grafting Surgery.
Chaudhry A; Roels C; Lee J
Can J Diabetes; 2022 Dec; 46(8):843-850. PubMed ID: 36068154
[TBL] [Abstract][Full Text] [Related]
27. Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Kelmenson DA; Burr K; Azhar Y; Reynolds P; Baker CA; Rasouli N
J Investig Med High Impact Case Rep; 2017; 5(2):2324709617712736. PubMed ID: 28634592
[TBL] [Abstract][Full Text] [Related]
28. The effect of preoperative sodium-glucose cotransporter 2 inhibitors on the incidence of perioperative metabolic acidosis: A retrospective cohort study.
Iwasaki Y; Sasabuchi Y; Horikita S; Furukawa T; Shiotsuka J; Lefor AK; Sanui M
BMC Endocr Disord; 2022 Aug; 22(1):209. PubMed ID: 35987618
[TBL] [Abstract][Full Text] [Related]
29. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
[TBL] [Abstract][Full Text] [Related]
30. Euglycemic Diabetic Ketoacidosis: A Review.
Modi A; Agrawal A; Morgan F
Curr Diabetes Rev; 2017; 13(3):315-321. PubMed ID: 27097605
[TBL] [Abstract][Full Text] [Related]
31. Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 Inhibitors: Clinical and Biochemical Characteristics of 29 Cases.
Stamatiades GA; D'Silva P; Elahee M; Viana GM; Sideri-Gugger A; Majumdar SK
Int J Endocrinol; 2023; 2023():6615624. PubMed ID: 37441367
[TBL] [Abstract][Full Text] [Related]
32. Prolonged euglycemic diabetic ketoacidosis triggered by a single dose of sodium-glucose cotransporter 2 inhibitor.
Miwa M; Nakajima M; Kaszynski RH; Goto H
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33028568
[TBL] [Abstract][Full Text] [Related]
33. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Khunti K; Aroda VR; Bhatt DL; Bozkurt B; Buse JB; Heerspink HL; Inzucchi SE; Lam CSP; Marx N; McMurray JJV; Solomon SD; Kosiborod MN
Diabetes Obes Metab; 2022 Nov; 24(11):2071-2080. PubMed ID: 35801339
[TBL] [Abstract][Full Text] [Related]
34. Euglycemic diabetic ketoacidosis: A missed diagnosis.
Nasa P; Chaudhary S; Shrivastava PK; Singh A
World J Diabetes; 2021 May; 12(5):514-523. PubMed ID: 33995841
[TBL] [Abstract][Full Text] [Related]
35. Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports.
Altowayan WM
Ann Med Surg (Lond); 2022 Dec; 84():104879. PubMed ID: 36582864
[TBL] [Abstract][Full Text] [Related]
36. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review.
El Ess MS; ElRishi MA
Ann Med Surg (Lond); 2023 May; 85(5):2097-2101. PubMed ID: 37228937
[TBL] [Abstract][Full Text] [Related]
37. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
38. Sodium-Glucose Cotransporter-2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis Followed by Excessively Low Carbohydrate Diet.
Tsutsui E; Hoshina Y; Homma H
Cureus; 2021 Jul; 13(7):e16085. PubMed ID: 34345561
[TBL] [Abstract][Full Text] [Related]
39. SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review.
Mahfooz RS; Khan MK; Al Hennawi H; Khedr A
Cureus; 2022 Jun; 14(6):e26267. PubMed ID: 35911365
[TBL] [Abstract][Full Text] [Related]
40. Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma.
Ahmed T; Karimi H; Hegde V; Lodhi SH
Cureus; 2021 Oct; 13(10):e19169. PubMed ID: 34873512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
